C4 Therapeutics, Inc. CCCC 深 滬
已收盤 05-08 16:00:00 美东时间
2.95
-0.030
-1.01%
華盛通- 最 高3.075
- 今 開2.98
- 成交量 134.43万股
- 最 低 2.922
- 昨 收 2.98
- 總市值 3.25亿
- 52周最高 3.82
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 1.21
- 委 比 -89.41%
- 總股本 1.10亿
- 歷史最高 51.21
- 量 比 0.47
- 振 幅 5.13%
- 歷史最低 1.06
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Roche To Acquire PathAI In Up To $1.05 Billion Deal To Expand Digital Pathology Push
Roche will acquire PathAI for up to $1.05 billion to expand AI-powered digital pathology and precision medicine capabilities.
05-08 02:56
FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment
Roche (RHHBY) Tuesday said that the US Food and Drug Administration has accepted its supplemental Biologics License Application for Gazyva/Gazyvaro for the treatment of systemic lupus erythematosus, w...
04-21 13:22
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod
Roche (RHHBY) announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics (SRPT) for the muscle-wasting disorder. Duchenne muscular...
04-16 22:53
C4 Therapeutics与罗氏扩大合作，达成逾10亿美元新癌症药物协议
C4 Therapeutics（CCCC.O）周四（4月9日）宣布，已与瑞士制药巨头罗氏（ROPC.S）签署一项新的合作协议，共同研发新型癌症药物，交易总价...
04-09 22:01
C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement
04-09 19:03
C4 Therapeutics expands Roche DAC collaboration with $20 million upfront payment
C4 Therapeutics expands Roche DAC collaboration with $20 million upfront payment C4 Therapeutics entered a new collaboration with Roche to discover and develop degrader-antibody conjugates for cancer. Agreement covers two DAC programs for undisclosed oncology targets, with an option for a third targ
04-09 18:59
C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed with cemsidomide,
03-25 19:09
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Cemsidomide, an oral IKZF1/3 degrader, has initiated a Phase 1b trial in combination with elranatamab and dexamethasone for relapsed/refractory multiple myeloma (RRMM). This trial aims to evaluate safety, tolerability, and anti-myeloma activity in up to 54 patients, exploring doses of 50, 75, and 100 µg. Secondary endpoints include overall response rate and complete response rate. The trial is part of a broader strategy to support cemsidomide's u...
03-25 11:00
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics granted 85,480 share stock options to a new employee, vesting over four years, with 25% after the first year and the rest in monthly installments. The exercise price matched the closing stock price on March 9, 2026.
03-09 20:01
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
